Table 2.
Summary results for 21 loci independently associated with prostate cancer risk.
| Marker | Locus | Positiona | Allelesb | EAF case | EAF control | ORc (95% CI) | P value | Padjvalued | Nearby genes |
|---|---|---|---|---|---|---|---|---|---|
| rs16902147 | 8q24 | 128474254 | GA | 0.07 | 0.04 | 1.86 (1.56–2.23) | 1.214E−11 | 3.525E−8 | CASC8 |
| rs79012498e | 8q24 | 128222502 | GA | 0.08 | 0.04 | 1.81 (1.53–2.15) | 1.507E−11 | 4.26E−8 | PRNCR1-CASC19 (intergenic) |
| rs11650494 | 17q21 | 44700185 | AG | 0.06 | 0.04 | 1.76 (1.46–2.12) | 2.817E−9 | 3.981E−6 | RP1-62O9.3-ZNF652 (intergenic) |
| rs58809953 | 8q24 | 128477243 | AG | 0.07 | 0.04 | 1.71 (1.43–2.04) | 2.855E−9 | 4.001E−6 | CASC8 |
| rs2074187e | 17q21 | 43285358 | AC | 0.07 | 0.04 | 1.66 (1.38–1.98) | 3.743E−8 | 3.752E−5 | SP6 |
| rs9656816 | 8q24 | 128603836 | GA | 0.17 | 0.12 | 1.43 (1.28–1.60) | 2.247E−10 | 5.165E−7 | CASC8-CASC11 (intergenic) |
| rs12795301 | 11q13 | 68748861 | AC | 0.13 | 0.098 | 1.42 (1.25–1.61) | 2.786E−8 | 2.894E−5 | RP11-554A11.8-MYEOV (intergenic) |
| rs995432 | 8p21 | 23578796 | GA | 0.53 | 0.45 | 1.38 (1.28–1.50) | 7.575E−16 | 3.003E−11 | RP11-583M2.2-NKX3-1 (intergenic) |
| rs4871798 | 8q24 | 128549145 | AG | 0.28 | 0.23 | 1.33 (1.22–1.46) | 3.105E−10 | 6.716E−7 | CASC8 |
| rs6985504 | 8q24 | 128565958 | AG | 0.35 | 0.30 | 1.27 (1.17–1.38) | 1.482E−8 | 1.649E−5 | CASC8 |
| rs1447293 | 8q24 | 128541502 | GA | 0.50 | 0.44 | 1.26 (1.16–1.36) | 5.639E−9 | 7.596E−6 | CASC8 |
| rs4793976 | 17q21 | 44135496 | GA | 0.39 | 0.33 | 1.26 (1.17–1.37) | 1.216E−8 | 1.397E−5 | LINC02086 |
| rs3760511 | 17q12 | 33180426 | CA | 0.49 | 0.43 | 1.26 (1.16–1.36) | 7.107E−9 | 9.01E−6 | HNF1B |
| rs4793529 | 17q24 | 66630231 | GA | 0.47 | 0.53 | 0.80 (0.74–0.87) | 2.416E−8 | 2.557E−5 | CASC17 |
| rs4871790 | 8q24 | 128510716 | CA | 0.45 | 0.50 | 0.80 (0.74–0.87) | 1.658E−8 | 1.809E−5 | CASC8 |
| rs587948 | 8q24 | 128410862 | CA | 0.34 | 0.39 | 0.80 (0.74–0.87) | 2.819E−8 | 2.894E−5 | CASC8 |
| rs2739459 | 19q13 | 56060886 | GA | 0.42 | 0.48 | 0.79 (0.73–0.86) | 2.186E−8 | 2.355E−5 | KLK2 |
| rs757138 | 7p15 | 27955927 | CA | 0.26 | 0.31 | 0.78 (0.72–0.85) | 1.114E−8 | 1.289E−5 | JAZF1 |
| rs266876 | 19q13 | 56052629 | GA | 0.19 | 0.23 | 0.76 (0.69–0.84) | 2.745E−8 | 2.868E−5 | KLK3 |
| rs10505477 | 8q24 | 128476625 | GA | 0.46 | 0.53 | 0.74 (0.69–0.80) | 6.105E−14 | 4.785E−10 | CASC8 |
| rs2659051 | 19q13 | 56037380 | GC | 0.12 | 0.16 | 0.72 (0.64–0.80) | 5.894E−9 | 7.847E−6 | AC011523.2 |
aPosition is based on Human Genome version 37p13 (hg19).
bEffect allele/Other allele.
cPer-allele odds ratio for the effect allele.
dAdjusted for false discovery rate (FDR) using the Benjamini–Hochberg method bold, newly reported for prostate cancer risk grey highlighted, variants associated with aggressive prostate cancer.
eMarkers associate with aggressive prostate cancer.